

Qasim A Rafiq

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9288646/publications.pdf>

Version: 2024-02-01

36
papers

1,354
citations

361413

20
h-index

414414

32
g-index

39
all docs

39
docs citations

39
times ranked

1245
citing authors

#	ARTICLE	IF	CITATIONS
1	Culture of human mesenchymal stem cells on microcarriers in a 5Â stirred-tank bioreactor. <i>Biotechnology Letters</i> , 2013, 35, 1233-1245.	2.2	160
2	A potentially scalable method for the harvesting of hMSCs from microcarriers. <i>Biochemical Engineering Journal</i> , 2014, 85, 79-88.	3.6	127
3	Systematic microcarrier screening and agitated culture conditions improves human mesenchymal stem cell yield in bioreactors. <i>Biotechnology Journal</i> , 2016, 11, 473-486.	3.5	117
4	Antimicrobial resistance mechanisms and potential synthetic treatments. <i>Future Science OA</i> , 2018, 4, FSO290.	1.9	76
5	Agitation conditions for the culture and detachment of hMSCs from microcarriers in multiple bioreactor platforms. <i>Biochemical Engineering Journal</i> , 2016, 108, 24-29.	3.6	73
6	Characterization of human mesenchymal stem cells from multiple donors and the implications for large scale bioprocess development. <i>Biochemical Engineering Journal</i> , 2016, 108, 14-23.	3.6	72
7	Expansion, harvest and cryopreservation of human mesenchymal stem cells in a serum-free microcarrier process. <i>Biotechnology and Bioengineering</i> , 2015, 112, 1696-1707.	3.3	71
8	Scale-up of human mesenchymal stem cell culture: current technologies and future challenges. <i>Current Opinion in Chemical Engineering</i> , 2013, 2, 8-16.	7.8	58
9	Lentiviral Vectors for T Cell Engineering: Clinical Applications, Bioprocessing and Future Perspectives. <i>Viruses</i> , 2021, 13, 1528.	3.3	45
10	Qualitative and quantitative demonstration of bead-to-bead transfer with bone marrow-derived human mesenchymal stem cells on microcarriers: Utilising the phenomenon to improve culture performance. <i>Biochemical Engineering Journal</i> , 2018, 135, 11-21.	3.6	41
11	Decentralized manufacturing of cell and gene therapies: Overcoming challenges and identifying opportunities. <i>Cytotherapy</i> , 2017, 19, 1140-1151.	0.7	40
12	Decentralised manufacturing of cell and gene therapy products: Learning from other healthcare sectors. <i>Biotechnology Advances</i> , 2018, 36, 345-357.	11.7	40
13	Cell therapy-processing economics: small-scale microfactories as a stepping stone toward large-scale macrofactories. <i>Regenerative Medicine</i> , 2018, 13, 159-173.	1.7	39
14	Expansion of human mesenchymal stem/stromal cells (hMSCs) in bioreactors using microcarriers: lessons learnt and what the future holds. <i>Biotechnology Advances</i> , 2020, 45, 107636.	11.7	38
15	Scalability and process transfer of mesenchymal stromal cell production from monolayer to microcarrier culture using human platelet lysate. <i>Cytotherapy</i> , 2016, 18, 523-535.	0.7	35
16	Process development of human multipotent stromal cell microcarrier culture using an automated high-throughput microbioreactor. <i>Biotechnology and Bioengineering</i> , 2017, 114, 2253-2266.	3.3	35
17	Serum-free process development: improving the yield and consistency of human mesenchymal stromal cell production. <i>Cytotherapy</i> , 2015, 17, 1524-1535.	0.7	34
18	Agitation and aeration of stirred-bioreactors for the microcarrier culture of human mesenchymal stem cells and potential implications for large-scale bioprocess development. <i>Biochemical Engineering Journal</i> , 2018, 136, 9-17.	3.6	28

#	ARTICLE	IF	CITATIONS
19	Centralised versus decentralised manufacturing and the delivery of healthcare products: A United Kingdom exemplar. <i>Cytotherapy</i> , 2018, 20, 873-890.	0.7	23
20	Developing an automated robotic factory for novel stem cell therapy production. <i>Regenerative Medicine</i> , 2016, 11, 351-354.	1.7	22
21	A quantitative approach for understanding small-scale human mesenchymal stem cell culture – implications for large-scale bioprocess development. <i>Biotechnology Journal</i> , 2013, 8, 459-471.	3.5	21
22	Establishing the scalable manufacture of primary human T cells in an automated stirred-tank bioreactor. <i>Biotechnology and Bioengineering</i> , 2019, 116, 2488-2502.	3.3	20
23	Demonstrating the Manufacture of Human CAR-T Cells in an Automated Stirred-Tank Bioreactor. <i>Biotechnology Journal</i> , 2020, 15, e2000177.	3.5	20
24	Design and development of a new ambr250® bioreactor vessel for improved cell and gene therapy applications. <i>Biotechnology Letters</i> , 2021, 43, 1103-1116.	2.2	19
25	Bioreactor Engineering Fundamentals for Stem Cell Manufacturing. , 2016, , 43-75.		16
26	Cell therapies: why scale matters. <i>Pharmaceutical Bioprocessing</i> , 2015, 3, 97-99.	0.8	15
27	Development of a process control strategy for the serum-free microcarrier expansion of human mesenchymal stem cells towards cost-effective and commercially viable manufacturing. <i>Biochemical Engineering Journal</i> , 2019, 141, 200-209.	3.6	14
28	CAR-T immunotherapies: Biotechnological strategies to improve safety, efficacy and clinical outcome through CAR engineering. <i>Biotechnology Advances</i> , 2019, 37, 107411.	11.7	12
29	Automating decentralized manufacturing of cell & gene therapy products. <i>Cell & Gene Therapy Insights</i> , 2016, 2, 489-497.	0.1	9
30	Mixing theory for culture and harvest in bioreactors of human mesenchymal stem cells on microcarriers. <i>Theoretical Foundations of Chemical Engineering</i> , 2016, 50, 895-900.	0.7	6
31	Process development and manufacturing approaches for mesenchymal stem cell therapies. , 2020, , 33-71.		6
32	A scaled-down model for the translation of bacteriophage culture to manufacturing scale. <i>Biotechnology and Bioengineering</i> , 2019, 116, 972-984.	3.3	5
33	The role of biopreservation in cell and gene therapy bioprocessing. <i>Cell & Gene Therapy Insights</i> , 2017, 3, 335-344.	0.1	5
34	The early career researcher's toolkit: translating tissue engineering, regenerative medicine and cell therapy products. <i>Regenerative Medicine</i> , 2015, 10, 989-1003.	1.7	4
35	Isolation of Mesenchymal Stem Cells from Bone Marrow Aspirate. , 2011, , 115-123.		1
36	Supply Chain Considerations and Strategies for Regenerative Medicine Products. , 2019, , .		0